Abstract
A significant proportion of germline mutations causing neurofibromatosis type 1 affect the correct splicing of the NF1 gene. Splicing is a complex mechanism by which introns from a pre-mRNA are removed. This process is finely regulated at the cellular level, and it has been shown that it can be modulated by using antisense oligonucleotides (AONs). Multiple studies have demonstrated the power of AONs in modulating abnormal splicing caused by constitutive DNA mutations, first in cultured cells, later in preclinical animal models, and currently in several promising clinical trials. A subset of splicing mutations, known as deep intronic mutations, create or strengthen acceptor or donor splice sites that, using a wild-type counterpart sequence, lead to the inclusion of a cryptic exon in the mRNA that will eventually produce an aberrant protein. In NF1, deep intronic mutations account for approximately 2 % of all NF1 germline mutations identified to date. Here we review different examples in which phosphorodiamidate morpholino oligomers (PMOs, a class of AONs) have been used to efficiently correct the abnormal splicing produced by NF1 deep intronic mutations. Reestablishment of normal splicing after PMO treatment has been analyzed at the mRNA level in different patient-derived primary cell cultures. Further, indirect evidence of neurofibromin function restoration has been assessed by quantifying the levels of active Ras before and after PMO treatment. In vitro results collected so far have demonstrated the considerable potential of this type of antisense therapy for deep intronic NF1-causing mutations, although further experimental studies, particularly in preclinical animal models, will be required in order to safely translate these results into clinical trials and eventually to the clinic. The success of clinical trials using AON technology for other mis-splicing mutations causing Duchenne muscular dystrophy (DMD) is encouraging and delineates a possible path from bench to bedside for these types of mutations causing neurofibromatosis type 1.
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
- Splice Site
- Duchenne Muscular Dystrophy
- Duchenne Muscular Dystrophy
- Duchenne Muscular Dystrophy Patient
- Aberrant Splice
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
13.1 Deep Intronic Mutations: A Specific Type of Splicing Mutation
Splicing is a complex and fine-tuned cellular mechanism consisting of the removal of introns from pre-mRNA transcripts to generate mature messenger RNAs. This essential process is completed by the spliceosome in different reactions that require the participation of several cis elements and trans-acting factors (reviewed in Hammond and Wood 2011). The recognition of intron–exon boundaries is crucial for correct splicing, so they are marked by highly conserved, almost invariant dinucleotides of the donor or 5′ intronic splice site (GT, in genomic DNA) and the intronic acceptor or 3′ splice site (AG, in genomic DNA). Other important genomic sequences for splice site identification are the branch site and the polypyrimidine tract, both of which are located upstream of the intronic acceptor site. Other relevant cis elements include nucleotides motifs representing splice site enhancers (SE) and silencers (SS) that are located within both intronic and exonic regions and participate in the recruitment of enhancer or silencer trans-acting factors to the splicing machinery. Genomic variants in the DNA sequences of these elements can alter the correct recognition of a bona fide exon or, alternatively, create a new cryptic splice site that can be identified by the splicing machinery. Hence, alterations in these DNA sequences produced by mutations can lead to errors in the splicing process, leading to exon skipping, partial exon deletion, or incorporation of an intronic region into the mature RNA. In all of these cases, either in-frame or out-of-frame abnormal transcripts may be produced by the mutated allele.
Classically, it was thought that splicing mutations were restricted to DNA changes that disrupt the invariant canonical donor and acceptor splice sites, so only these mutations were reported as splicing mutations in mutation databases (currently fewer than 10 % of all point mutations reported in the Human Gene Mutation Database (HGMD Professional 2011.4; http://www.hgmd.org). However, over the last decade, a large number of studies have identified other types of mutation that also affect the correct splicing of a gene, particularly in genetic analyses that have been focused on large genes, using RNA-based approaches for constitutive mutation detection (Teraoka et al. 1999; Ars et al. 2000). These findings have served to extend the group of disease-causing mutations that impact splicing to a range of different mutation types (nonsense, missense, frameshift, etc.) affecting any sequence that is important for splice site recognition and mRNA processing. For example, the largest unbiased comprehensive study of >2,000 unrelated NF1 patients found that approximately 30 % of NF1 point mutations affected correct mRNA splicing (L Messiaen, personal communication). A small subset of these mutations (about 2 %) (Messiaen and Wimmer 2008; Pros et al. 2008; Wimmer et al. 2007) comprises single-nucleotide changes in sequences residing deep within introns, which create novel donor or acceptor sites that, in conjunction with a nearby cryptic splice counterpart, define a new cryptic exon that the spliceosome then incorporates into mature messenger RNA. Most of these mutations are missed by conventional DNA-based mutation detection techniques because they are located deep within intronic sequences, distant from intron–exon boundaries, and hence are not scanned when this type of mutation detection approach is employed. Moreover, a high proportion of these mutations create mRNAs with premature termination codons (PTC), rendering the transcripts susceptible to degradation by the nonsense-mediated mRNA decay (NMD) machinery. It is therefore desirable to use an NMD inhibitor prior to RNA extraction to be able to detect the mis-splicing effects characteristic of deep intronic mutations (Messiaen et al. 2000). Together, these observations suggest that the frequency of this type of mutation has probably been underestimated for most studied genes.
13.2 Use of Antisense Oligonucleotides to Modulate Aberrant Splicing
In recent years, antisense oligonucleotide (AON)-mediated therapies have been increasingly used to restore gene function by modulating aberrant splicing in different scenarios created by disease-causing mutations. Correction of altered RNA splicing can be achieved by masking a splice motif with AONs complementary to a specific sequence of the pre-mRNA of interest, thereby inhibiting by steric hindrance the recognition of this region by the splicing machinery. The first indication that AONs could be used as therapeutic agents for genetic diseases was obtained from studies in β-thalassemia, in which abnormal splicing of the beta-globin (HBB) gene due to activation of intronic cryptic sites was corrected using an AON approach (Dominski and Kole 1993). Different applications of AON-dependent splicing modulation have been described in the literature, including forcing the skipping of one or more exons flanking a frameshift in order to restore the open reading frame of a gene (Aartsma-Rus et al. 2003, 2004), forcing the selection of an alternative splice site in order to prevent the synthesis of pathogenic transcripts (Mercatante and Kole 2002), preventing the inclusion of an aberrant cryptic exon inserted into the mRNA due to a deep intronic mutation (Du et al. 2007; Rincon et al. 2007; Pros et al. 2009; Rodriguez-Pascau et al. 2009; Vega et al. 2009), and inducing the elimination of in-frame exons that contain a pathogenic mutation (Aartsma-Rus et al. 2003, 2004; reviewed in Perez et al. 2010).
Deep intronic mutations are ideal targets for AON function because they are located within intronic regions, leaving bona fide splice sites intact. Steric blockage by AONs of a newly created splice site prevents the splicing machinery from recognizing the cryptic exon and promotes normal splicing.
13.2.1 Types of AON and Delivery Vehicles
The development of AON technology as a successful means of applying antisense therapy had to overcome a range of obstacles and continues to face several technical challenges, some related to AON stability and cellular delivery.
To avoid degradation by cellular nucleases, different analogs have been used for AON design, including phosphorodiamidate morpholino oligomers (PMO) (Summerton 1999), locked nucleic acids (LNA) (Koshkin and Wengel 1998), peptide nucleic acids (PNA) (Larsen et al. 1999), and 2′-O-methyl phosphorothioate (2′OMe) (Manoharan 1999). All have shown stability against degradation, high target affinity, and good biological activity (reviewed in (Kurreck 2003). Antisense phosphorodiamidate morpholino oligomers (PMOs) have been used successfully for splicing modulation in neurofibromatosis type 1 (Pros et al. 2009; Fernandez-Rodriguez et al. 2011). PMOs are analogs of oligonucleotides with a six-membered morpholinoring, replacing the ribose or deoxyribose backbone, and uncharged phosphorodiamidate intersubunit linkages. In addition to high binding specificity, stability, and resistance to nucleases, PMOs exhibit highly durable activity (Summerton and Weller 1997). Due to these advantageous properties, PMOs have been used for therapeutic purposes in several disorders, including β-thalassemia (Lacerra et al. 2000; Suwanmanee et al. 2002), Duchenne muscular dystrophy (McClorey et al. 2006), Hutchinson–Gilford progeria syndrome (Scaffidi and Misteli 2005), ataxia-telangiectasia (Du et al. 2007), and propionic and methylmalonic acidemias (Rincon et al. 2007).
Another important aspect in AON technology is the delivery of the antisense oligomers into target cells. Initially, different techniques were developed to transfect in vitro cell cultures, including electroporation, liposomes, cationic polymers, and other endosomal escape reagents (Thierry et al. 2003; Merdan et al. 2002). However, for AON delivery in vivo, these procedures were characterized by low efficiency and inadequate levels of toxicity. In this context, modification of AON ends to facilitate cellular delivery has been found to be a more effective solution than the use of unmodified forms. Two promising examples are Morpholino oligos linked to cell-penetrating peptides (PPMOs) and Vivo-Morpholinos (Moulton and Jiang 2009). PPMOs are typically an arginine-rich cell-penetrating peptide linked to a Morpholino oligo. Cell-penetrating peptides offer two advantages over unmodified Morpholinos: enhanced uptake into endosomes and enhanced endosomal escape (Abes et al. 2008). Vivo-Morpholinos are eight guanidinium groups on a dendrimeric scaffold linked to a Morpholino oligo (Li and Morcos 2008) that facilitates efficient delivery into most mouse tissues (Morcos et al. 2008) and has been used successfully as a therapeutic agent in different animal models (e.g., Osorio et al. 2011).
13.3 Use of Antisense Oligonucleotides to Reverse the Effect of Deep Intronic NF1 Mutations
As mentioned previously, approximately 2 % of germline NF1 mutations are deep intronic nucleotide changes that activate or create novel splice sites, causing the pathogenic inclusion of cryptic exons in mRNA (Messiaen and Wimmer 2008; Pros et al. 2008) (summarized in Table 13.1). These mutations are an ideal target for antisense therapies since the bona fide splice sites remain intact, conserving their potential for normal splicing. Next, a summary of the results obtained to date on the use of AONs to reverse the effects of NF1 deep intronic mutations is presented (Pros et al. 2009; Fernandez-Rodriguez et al. 2011), focusing on the differences between distinct mutations and cell-type specificities, the required doses and duration of AON effects (in our case, PMOs), the mode of action, and the impact on neurofibromin function.
13.3.1 Effects of PMOs Are Mutation-Dependent and Variable Between Cell Types
To test the efficiency of PMO treatment in restoring normal splicing for this type of mutation, samples were obtained from seven patients with four independent NF1 germline deep intronic mutations (Table 13.1, Fig. 13.1). Primary lymphocyte and fibroblast cell lines were derived from these patients, and specific PMOs were designed to block the effects of mutations causing the inclusion of cryptic exons in the NF1 gene. Three of the studied mutations generated a cryptic donor splice site (c.288+2025T>G, c.5749+332A>G and c.7908-321C>G), whereas the fourth generated a cryptic acceptor site (c.3198-314G>A). All mutations used a wild-type counterpart to insert a cryptic exon into the mature mRNA (Fig. 13.1), which either led to the generation of out-of-frame transcripts susceptible to degradation by the NMD machinery or produced a truncated form of neurofibromin. All PMOs were designed, synthesized, and purified by Gene Tools (Philomath, OR). For one of the mutations (c.3198-314G>A), PMOs were also designed to block the recognition of the two wild-type counterpart sequences used as donor sites for cryptic exon inclusion (Fig. 13.1). Optimal conditions for PMO treatment were established using fibroblasts, and, when possible, PMO treatment was subsequently studied using EBV-transformed lymphocytes.
To determine the effect of PMO concentration on aberrant splicing correction, a dose–response experiment was performed for different mutations, in which fibroblasts were treated with three different PMO concentrations (5, 10 and 20 μM) for 24 h (Fig. 13.1). In the absence of PMO, the percentage of aberrantly spliced transcripts (containing the cryptic exon) was approximately 10–15 % of the total NF1 mRNA (wild-type + aberrantly spliced transcripts). As envisaged, the low percentage of cryptic exon-containing NF1 mRNAs was the result of partial degradation by the NMD machinery and the production of wild-type transcripts from the mutated allele, due to partial recognition of bona fide intron–exon boundaries by the splicing machinery. When cells were treated with the specifically designed PMO, either complete correction or a dose-dependent correction of aberrant splicing was observed, depending upon the mutation. 20 μM was found to be the optimal concentration of PMO for most mutations tested and was therefore used for the remaining mutations and experiments (Fig. 13.1). The response to PMO treatment was clearly mutation-dependent. By contrast, cells from different patients carrying the same NF1 mutation (e.g., c.5749+332A>G and c.7908-321C>G) exhibited similar results upon addition of PMO (Pros et al. 2009).
To evaluate the effect of time on mutation correction after Morpholino treatment, a time course was performed for three of the mutations using fibroblast cell lines (Pros et al. 2009). In general, the efficiency of NF1 splicing correction in fibroblasts after 24 h of treatment ranged from 87 to 100 % for the different mutations.
Several factors could account for the variance in PMO activity between the mutations studied, for example, differences in the strength of the cryptic acceptor/donor splice sites or variations in the extent to which PMO accesses the pre-mRNA secondary structures. Different strategies could be used to enhance the PMO-dependent restoration of normal splicing for these mutations, including the following: designing a different PMO for blocking the mutation site; using a combination of Morpholinos, one directed at the specific mutation site and the other blocking the wild-type cryptic site used as a counterpart; using a Morpholino to target only the latter; designing Morpholinos to target exon splicing enhancer (ESE) elements. Reports have indicated that the use of PMOs may, in some cases, be more efficient for one of the cryptic splice sites than the other (Du et al. 2007). In this sense, our results with mutation c.3198-314G>A, in which three PMOs were designed to block all of the cryptic splice sites used, indicated that although each PMO was able to reduce the levels of mutant transcripts, complete correction was only observed when a combination of the three PMOs was used (Fig. 13.1), as has also been described for other genetic disorders (Gurvich et al. 2008).
To gain insight into the cell-type specificities of Morpholino treatment, in addition to fibroblasts, transformed lymphocytes derived from the same patients were also analyzed. The highest degree of normal splicing restoration (although not complete) in EBV-transformed lymphocyte cell lines was observed at 72 h, following treatment with 50 μM PMO (Fig. 13.1). Lower concentrations of Morpholino were also tested but were found to be less effective. In general, a lower degree of aberrant splicing correction was observed in transformed lymphocyte cell lines (30–70 % depending upon the mutation), and a higher concentration of Morpholino, together with a longer exposure time, was needed to produce similar effects to those observed in fibroblasts. The differences between the effects observed in fibroblasts and lymphocytes could be explained by the inherent difficulty of transfecting lymphocyte cell lines (Galletti et al. 2007; Seiffert et al. 2007). The authors of another comparative study, using electroporation to deliver Morpholino into cells, achieved similar transfection efficiencies in dermal fibroblasts and B-lymphocyte cell lines. However, different electroporation protocols were required for the two cell types. It was shown that a higher number of electroporation cycles and a higher Morpholino concentration were needed to achieve the same efficiency in lymphocytes as in fibroblasts (Scaffidi and Misteli 2005). The different conditions required for the two cell types were consistent with findings presented by other groups using the same delivery systems in lymphocytes (Du et al. 2007) and fibroblasts (Rincon et al. 2007).
13.3.2 Effects of PMOs Are Durable, Specific, and Impact on the Function of Neurofibromin
The parallel use of a different control PMO in all of the assays revealed the specificity of the mutation-specific PMOs (Fig. 13.1). Only mutation-specific PMOs had a corrective effect on aberrant splicing in all cases, indicating that the effect of PMO treatment was sequence-specific. The stability and duration of the effect of PMO treatment on aberrant splicing correction were assessed in primary fibroblast cell cultures. Although differences were observed for distinct mutations, near-complete correction was maintained for 20 days after PMO administration in all cases (Pros et al. 2009).
The mode of action of Morpholinos on NF1 mutations was also investigated. To rule out the possibility that the decreased aberrant transcript levels after PMO treatment was caused by an enhancement of the NMD pathway, fibroblasts from different patients were treated with puromycin (an NMD inhibitor) in the presence or absence of PMO. A total or considerable correction of aberrant splicing after PMO treatment (depending on the mutation) was observed in the presence of puromycin, which indicated that the PMOs acted directly on NF1 splicing, independently of the NMD mechanism (Pros et al. 2009). Moreover, an increase in wild-type transcript levels (relative to control genes) was observed after PMO treatment, which confirmed that PMO induced correct splicing by blocking the recognition of the new splice site created by the mutation (Pros et al. 2009). Taken together, these results indicate that PMO acts in a sequence-specific manner by preventing the splicing machinery from recognizing the newly created aberrant splice sites in the NF1 gene.
Finally, since neurofibromin function cannot be assessed directly, an indirect functional analysis was performed to confirm that correction of aberrant splicing by PMO treatment was also attained at the functional level. Since neurofibromin is a well-characterized negative regulator of Ras, Ras-GTP levels in patient-derived primary fibroblast cultures were measured. Fibroblast cultures carrying four different deep intronic mutations were evaluated by comparing Ras-GTP levels before and after specific PMO treatment. Cell lysates were prepared, and a Ras activation assay was performed (Fig. 13.2). Levels of active Ras-GTP in untreated fibroblast cultures from all patients were higher than the levels found in the wild-type control fibroblasts, which was consistent with the observation of lower neurofibromin activity in mutant fibroblasts. However, Ras-GTP levels of mutant fibroblasts decreased significantly with PMO treatment, reaching levels comparable to those of wild-type control fibroblasts. This result not only suggested that PMO treatment corrected the aberrant splicing but also indicated that this correction led to the restoration of WT neurofibromin, increasing its overall GAP activity toward Ras proteins.
13.4 AON Therapeutics: From Bench to Bedside
No definitive conclusions have been reached about the in vivo applicability of AON technology for the treatment of NF1 patients with deep intronic mutations; to date, no preclinical animal model or a clinical trial has been performed using this antisense technology for NF1. However, the success of recent clinical trials using AON-directed exon 51 skipping in patients with Duchenne muscular dystrophy (DMD) has created reasonable expectations of eventual success (trials are currently being extended to other exons) (reviewed in Muntoni and Wood 2011; van Putten and Aartsma-Rus 2011). The path from bench to bedside using AON technology is subject to the step-by-step fulfillment of certain requirements, as is the case for any therapeutic agent to treat human disease. The steps comprise in vitro proof of concept followed by the successive phases of clinical trials. The best example of AON technology as a therapeutic strategy is DMD. First, a proof of principle was obtained using cultures of healthy and patient-derived primary human myoblasts (Aartsma-Rus et al. 2002, 2003, 2004). A mouse model of DMD, mdx mice, was used for in vivo preclinical trials using different AON chemistries (Goyenvalle et al. 2010; Heemskerk et al. 2009; Wu et al. 2008; Yin et al. 2009). Two exploratory clinical trials using AONs were performed, with the aim of correcting the reading frame of mRNAs encoding a truncated form of dystrophin and producing transcripts similar to those found in patients with Becker muscular dystrophy (a milder form of the disease). The approaches in both trials consisted in forcing the skipping of exon 51 of the DMD gene. One used 2′OMePS (PRO051) (van Deutekom et al. 2007) and the other morpholino oligomers (AVI-4658) (Kinali et al. 2009). In both cases, the direct injection of AON into the muscle corrected significant levels of dystrophin expression, proving the feasibility of the technology without generating clinically important side effects. In a recent phase, I–IIa clinical trial, systemic administration by subcutaneous injection of PRO051 was found to correct dystrophin expression, with no serious adverse events and a modest improvement in the walking capacity of treated patients, although with considerable variance between patients (Goemans et al. 2011). The first systemic clinical trial with PMOs also showed satisfactory levels of dystrophin restoration after treatment (Cirak et al. 2011). More clinical trials for DMD are currently in progress, including phase III trials and some studies involving other exons of the DMD gene (Muntoni 2010; van Putten and Aartsma-Rus 2011). For other muscular dystrophies and other diseases, AON therapy is at different points on the path from bench to bedside (Muntoni 2010; van Putten and Aartsma-Rus 2011).
Certain challenges remain in the development of AON therapies (Goyenvalle et al. 2010), such as ensuring efficient AON delivery to all affected tissues or even directing tissue-specific targeting. The first AON chemistries used in clinical trials exhibited poor cellular uptake and a relatively rapid clearance from the circulation, requiring repeated administration. However, recent developments using cell-penetrating peptides conjugated to PMOs (PPMO) or Vivo-Morpholinos have addressed most of these delivery issues, representing a major step forward and revealing what could prove to be an effective strategy, although with room for improvement (Moulton and Jiang 2009; Muntoni 2010).
There are certain limitations to the development of AON therapies, mainly as a result of regulatory constraints and safety considerations. Data collected from the first DMD clinical trials are encouraging, but the number of patients involved has been low in number, the final dosing regimens need to be properly established, and data for treatments longer than 1 year must be provided. It has not yet been confirmed that long-term AON treatment is safe and improves the DMD patient’s quality of life, so a cautious view should be taken for now. Given that each AON is mutation-specific (or exon-specific, in the case of forcing skipping), one of the caveats of clinical trials using this technology is the low number of patients that could be recruited, since a personalized AON approach will be required for most diseases. Under current regulations, each AON is considered a new drug, so each AON targeting a different exon or mutation would have to undergo the many different steps of clinical development, with all the costs that this process entails (Muntoni 2010). To overcome this hurdle, and since AONs of a certain chemical class generally show more similarities than differences, the same type of chemically identical AONs should be treated as a single drug class, irrespective of the mutation or exon involved, as this would enable sufficient clinical data to be accumulated to develop the technology as a valid therapy for deep intronic mutations and other RNA mis-splicing diseases.
Much work remains to be done in the case of NF1, starting with preclinical animal models. If successful, the foundations provided by DMD AON therapeutics may facilitate clinical trials with NF1 patients, potentially leading to reasonable treatment opportunities for NF1 patients with deep intronic alterations causing mis-splicing and possibly also for patients with other AON-treatable NF1 mutations.
13.5 Conclusions
Some NF1-causing mutations are located well inside intronic regions of the NF1 gene. These deep intronic mutations lead to the inclusion of a cryptic exon in the NF1 mRNA, eventually generating an aberrant neurofibromin. We reviewed a body of results that prove the effectiveness of PMOs in correcting abnormal splicing produced by these mutations in the NF1 gene. Lymphocyte and fibroblast primary cultures derived from seven NF1 patients, bearing four independent NF1 mutations, were tested. In all cases, PMOs restored the correct splicing of the gene and neurofibromin function, indirectly evaluated by the capacity to downregulate Ras-GTPase. Overall, these results represent a proof of concept for the in vitro capacity of PMOs to correct the effect of the NF1-causing mutations examined. The success of current clinical trials using AON technology to treat DMD patients should spur the development of NF1 preclinical animal models. Deep intronic mutations account for approximately 2 % of all NF1 constitutional mutations reported to date. AON technology could be applied to patients carrying this type of mutation and perhaps also other types of mutation that generate aberrant NF1 transcripts.
References
Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC (2002) Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord 12(Suppl 1):S71–S77
Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F, van Ommen GJ, van Deutekom JC (2003) Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12(8):907–914
Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT, van Deutekom JC (2004) Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 74(1):83–92
Abes R, Moulton HM, Clair P, Yang ST, Abes S, Melikov K, Prevot P, Youngblood DS, Iversen PL, Chernomordik LV et al (2008) Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies. Nucleic Acids Res 36(20):6343–6354
Ars E, Serra E, Garcia J, Kruyer H, Gaona A, Lazaro C, Estivill X (2000) Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum Mol Genet 9(2):237–247 [published erratum appears in Hum Mol Genet 2000 9(4):659]
Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ et al (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378(9791):595–605
Dominski Z, Kole R (1993) Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA 90(18):8673–8677
Du L, Pollard JM, Gatti RA (2007) Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides. Proc Natl Acad Sci USA 104(14):6007–6012
Fernandez-Rodriguez J, Castellsague J, Benito L, Benavente Y, Capella G, Blanco I, Serra E, Lazaro C (2011) A mild neurofibromatosis type 1 phenotype produced by the combination of the benign nature of a leaky NF1-splice mutation and the presence of a complex mosaicism. Hum Mutat 32(7):705–709
Galletti R, Masciarelli S, Conti C, Matusali G, Di Renzo L, Meschini S, Arancia G, Mancini C, Mattia E (2007) Inhibition of Epstein Barr Virus LMP1 gene expression in B lymphocytes by antisense oligonucleotides: uptake and efficacy of lipid-based and receptor-mediated delivery systems. Antiviral Res 74(2):102–110
Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, Holling T, Janson AA, Platenburg GJ, Sipkens JA et al (2011) Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N Engl J Med 364(16):1513–1522
Goyenvalle A, Babbs A, Powell D, Kole R, Fletcher S, Wilton SD, Davies KE (2010) Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol Ther 18(1):198–205
Gurvich OL, Tuohy TM, Howard MT, Finkel RS, Medne L, Anderson CB, Weiss RB, Wilton SD, Flanigan KM (2008) DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy. Ann Neurol 63(1):81–89
Hammond SM, Wood MJ (2011) Genetic therapies for RNA mis-splicing diseases. Trends Genet 27(5):196–205
Heemskerk H, de Winter CL, van Ommen GJ, van Deutekom JC, Aartsma-Rus A (2009) Development of antisense-mediated exon skipping as a treatment for Duchenne muscular dystrophy. Ann N Y Acad Sci 1175:71–79
Jeong SY, Park SJ, Kim HJ (2006) The spectrum of NF1 mutations in Korean patients with neurofibromatosis type 1. J Korean Med Sci 21(1):107–112
Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P et al (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8(10):918–928
Koshkin AA, Wengel J (1998) Synthesis of novel 2′,3′-linked bicyclic thymine ribonucleosides. J Org Chem 63(8):2778–2781
Kurreck J (2003) Nucleic acids chemistry and biology. Angew Chem Int Ed Engl 42(44):5384–5385
Lacerra G, Sierakowska H, Carestia C, Fucharoen S, Summerton J, Weller D, Kole R (2000) Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci USA 97(17):9591–9596
Larsen HJ, Bentin T, Nielsen PE (1999) Antisense properties of peptide nucleic acid. Biochim Biophys Acta 1489(1):159–166
Li YF, Morcos PA (2008) Design and synthesis of dendritic molecular transporter that achieves efficient in vivo delivery of morpholino antisense oligo. Bioconjug Chem 19(7):1464–1470
Manoharan M (1999) 2′-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim Biophys Acta 1489(1):117–130
McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, Fletcher S, Wilton SD (2006) Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord 16(9–10):583–590
Mercatante DR, Kole R (2002) Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression. Biochim Biophys Acta 1587(2–3):126–132
Merdan T, Kopecek J, Kissel T (2002) Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 54(5):715–758
Messiaen L, Wimmer K (2008) NF1 mutational spectrum. In: Kaufmann D (ed) Neurofibromatoses, Monographs in human genetics. Karger, Basel, pp 63–77
Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, Speleman F, Paepe AD (2000) Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 15(6):541–555
Morcos PA, Li Y, Jiang S (2008) Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. Biotechniques 45(6):613–614, 616, 618 passim
Moulton JD, Jiang S (2009) Gene knockdowns in adult animals: PPMOs and vivo-morpholinos. Molecules 14(3):1304–1323
Muntoni F (2010) The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009. Neuromuscul Disord 20(5):355–362
Muntoni F, Wood MJ (2011) Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov 10(8):621–637
Osorio FG, Navarro CL, Cadinanos J, Lopez-Mejia IC, Quiros PM, Bartoli C, Rivera J, Tazi J, Guzman G, Varela I et al (2011) Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med 3(106):106ra107
Perez B, Rodriguez-Pascau L, Vilageliu L, Grinberg D, Ugarte M, Desviat LR (2010) Present and future of antisense therapy for splicing modulation in inherited metabolic disease. J Inherit Metab Dis 33(4):397–403
Perrin G, Morris MA, Antonarakis SE, Boltshauser E, Hutter P (1996) Two novel mutations affecting mRNA splicing of the neurofibromatosis type 1 (NF1) gene. Hum Mutat 7(2):172–175
Pros E, Fernandez-Rodriguez J, Canet B, Benito L, Sanchez A, Benavides A, Ramos FJ, Lopez-Ariztegui MA, Capella G, Blanco I et al (2009) Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations. Hum Mutat 30(3):454–462
Pros E, Gomez C, Martin T, Fabregas P, Serra E, Lazaro C (2008) Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations. Hum Mutat 29(9):E173–E193
Raponi M, Upadhyaya M, Baralle D (2006) Functional splicing assay shows a pathogenic intronic mutation in neurofibromatosis type 1 (NF1) due to intronic sequence exonization. Hum Mutat 27(3):294–295
Rincon A, Ugarte M, Aguado C, Desviat LR, Sanchez-Alcudia R, Perez B (2007) Propionic and methylmalonic acidemia: antisense therapeutics for intronic variations causing aberrantly spliced messenger RNA. Am J Hum Genet 81(6)
Rodriguez-Pascau L, Coll MJ, Vilageliu L, Grinberg D (2009) Antisense oligonucleotide treatment for a pseudoexon-generating mutation in the NPC1 gene causing Niemann-Pick type C disease. Hum Mutat 30(11):E993–E1001
Scaffidi P, Misteli T (2005) Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 11(4):440–445
Seiffert M, Stilgenbauer S, Dohner H, Lichter P (2007) Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia 21(9):1977–1983
Spits C, De Rycke M, Van Ranst N, Joris H, Verpoest W, Lissens W, Devroey P, Van Steirteghem A, Liebaers I, Sermon K (2005) Preimplantation genetic diagnosis for neurofibromatosis type 1. Mol Hum Reprod 11(5):381–387
Summerton J (1999) Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1489(1):141–158
Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7(3):187–195
Suwanmanee T, Sierakowska H, Fucharoen S, Kole R (2002) Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder. Mol Ther 6(6):718–726
Teraoka SN, Telatar M, Becker-Catania S, Liang T, Onengut S, Tolun A, Chessa L, Sanal O, Bernatowska E, Gatti RA et al (1999) Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. Am J Hum Genet 64(6):1617–1631
Thierry AR, Vives E, Richard JP, Prevot P, Martinand-Mari C, Robbins I, Lebleu B (2003) Cellular uptake and intracellular fate of antisense oligonucleotides. Curr Opin Mol Ther 5(2):133–138
van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM et al (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357(26):2677–2686
van Putten M, Aartsma-Rus A (2011) Opportunities and challenges for the development of antisense treatment in neuromuscular disorders. Expert Opin Biol Ther 11(8):1025–1037
Vega AI, Perez-Cerda C, Desviat LR, Matthijs G, Ugarte M, Perez B (2009) Functional analysis of three splicing mutations identified in the PMM2 gene: toward a new therapy for congenital disorder of glycosylation type Ia. Hum Mutat 30(5):795–803
Wimmer K, Roca X, Beiglbock H, Callens T, Etzler J, Rao AR, Krainer AR, Fonatsch C, Messiaen L (2007) Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5′ splice-site disruption. Hum Mutat 28(6):599–612
Wu B, Moulton HM, Iversen PL, Jiang J, Li J, Li J, Spurney CF, Sali A, Guerron AD, Nagaraju K et al (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 105(39):14814–14819
Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, Iverson PL, Wood MJ (2009) A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18(22):4405–4414
Acknowledgements
We thank the patients who participated in this study for their willingness to contribute and to collaborate in all the proposed experiments. We thank Josep Biayna for critical advice and corrections to the manuscript as well as all the members of the ICO-IMPPC Neurofibromatosis working group. The authors wish to extend special thanks to the Asociación Española de Afectados de Neurofibromatosis for the grant awarded and for their constant support during the research. We would like also to thank the Asociación Española Contra el Cáncer, which recognized our group as one of the 2010 stable cancer research groups. Contract grant sponsor: Spanish Health Research Fund; Carlos III Health Institute; Catalan Health Institute and Autonomous Government of Catalonia. Contract grant numbers: ISCIIIRETIC: RD06/0020/1051, RD06/0020/1050, 2009SGR290, PI10/01422, CA08/00248.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lázaro, C., Fernández-Rodríguez, J., Serra, E. (2012). Deep Intronic NF1 Mutations and Possible Therapeutic Interventions. In: Upadhyaya, M., Cooper, D. (eds) Neurofibromatosis Type 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-32864-0_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-32864-0_13
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-32863-3
Online ISBN: 978-3-642-32864-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)